Robotic Radiosurgery System Market Size, Share, and Trends Analysis - Global - 2025-2031 - Includes: Capital Equipment Market and Service and Maintenance Revenue Market

Global Robotic Radiosurgery System Market Report, 2025 Edition

Executive Summary

The global robotic radiosurgery system market was valued at approximately $350 million in 2024. The market is expected to grow at an 11.1 percent CAGR to reach nearly $720 million by 2031.

This report provides comprehensive coverage of capital equipment, services and maintenance revenue, and procedure volumes associated with robotic radiosurgery systems across all major regions. It quantifies units, average selling prices, market values, growth rates, and company shares, while also examining clinical trends, adoption barriers, regulatory influences, and technology advancements. The report includes forecasts to 2032 and historical data to 2022.

Robotic radiosurgery systems are playing an increasingly important role in cancer care as patient volumes rise, treatment expectations evolve, and health systems pursue more accurate, noninvasive therapeutic options. The precision and motion management capabilities of robotic platforms such as CyberKnife deliver targeted radiation treatment while minimizing damage to surrounding tissues. This has become a central driver behind growing clinical adoption in both advanced and emerging markets.

Expanding clinical indications, higher procedure throughput, and improvements in patient outcomes are supporting the continued upward trajectory of this market. At the same time, the shift toward more personalized therapy is increasing interest in technologies that can deliver precise, real time tumor tracking. These trends, combined with strong manufacturer investment and emerging partnerships between robotics developers and imaging or AI-based planning companies, are expected to accelerate growth across the forecast period.

Market Overview

Robotic radiosurgery combines image guidance, motion tracking, and robotic positioning to deliver high dose radiation with exceptional accuracy. The technology is most commonly used for brain, head and neck, spinal, and lung cancers, but indications continue to expand as systems evolve.

Accuray’s CyberKnife remains the defining technology in this field. Its ability to deliver treatment without rigid stereotactic frames, while compensating for patient and tumor motion in real time, has set the clinical benchmark. As cancer incidence rises globally, the need for noninvasive and highly precise treatment options is increasing. This is shaping the long term trajectory of the global robotic radiosurgery system market.

The market is influenced by several interconnected factors, including the rising number of cancer cases, the effectiveness of radiation as part of curative treatment plans, the preference for systems that allow outpatient care, and institutional efforts to differentiate offerings by investing in advanced technologies. Although robotic radiosurgery is not the only option for radiation therapy, its precision, lower complication rates, and improving workflow efficiencies are allowing it to gain share in specialized centers.

Nonetheless, competition from traditional surgery, chemotherapy, and other radiation modalities remains an important limiter. High system cost and training time continue to constrain adoption for smaller hospitals and regions with limited investment capacity. Even so, the market outlook remains strongly positive, with continuous improvements in planning software, imaging integration, and automation expected to increase confidence among clinicians and broaden system utilization.

Market Drivers

Increasing Cancer Cases

Cancer incidence continues to rise worldwide due to aging populations, lifestyle factors, and earlier detection. The WHO projects more than 35 million new cancer cases globally by 2050. This represents a significant increase over the 20 million cases estimated in 2022. Higher disease prevalence directly supports demand for treatment technologies, including robotic radiosurgery systems.

In the United States alone, nearly 1.9 million new cancer diagnoses occur each year, with more than 600,000 related deaths. As health systems expand treatment capacity, they are increasingly investing in platforms that allow for precise, targeted therapy. Robotic radiosurgery fits this need by offering high radiation doses delivered with submillimeter accuracy, reducing damage to surrounding tissue.

Increasing Adoption of Radiosurgery for Cancer Treatment

Radiation therapy contributes to approximately 40 percent of all curative cancer treatments, yet global utilization rates remain below 50 percent. As clinical guidelines continue to emphasize the value of radiation in multimodal treatment plans, more patients are being directed toward radiation-based options.

Robotic radiosurgery systems offer unique precision, making them appealing for cases where tumors are difficult to access or where open surgery is not viable. Evidence supporting favorable outcomes with robotic radiosurgery continues to accumulate, encouraging hospitals to broaden their treatment offerings.

Clinical Benefits

CyberKnife and similar systems allow for real time tumor tracking and adaptive movement compensation. This reduces radiation exposure to adjacent structures and enhances treatment durability.

Clinical benefits include:

Increased surgical precision

Fewer complications

Reduced damage to healthy tissue

Lower likelihood of repeat procedures

Faster patient recovery times

As more centers publish outcome data, confidence in robotic radiosurgery systems grows. These benefits support long term adoption and reinforce purchasing decisions among hospitals and cancer institutes.

Market Limiters

Cost of Using Robotic Systems

Robotic radiosurgery systems are expensive investments for healthcare institutions. The CyberKnife platform typically costs well over $3 million, with additional costs for installation, shielding, planning software, and staffing.

This high investment may limit adoption, especially among:

Smaller hospitals

Community cancer centers

Regions with limited reimbursement

Countries with strict capital expenditure policies

Because robotics companies derive substantial revenue from system sales, cost remains a central limitation to market expansion.

Alternative Treatment Methods

Traditional surgery, brachytherapy, conventional stereotactic radiosurgery, chemotherapy, and targeted drug treatments all remain common cancer treatments. Many are less costly and have established reimbursement pathways.

Although robotic radiosurgery offers unique benefits, the presence of many alternative clinical options limits how quickly robotic platforms can penetrate the market. Some institutions prioritize lower cost modalities despite the advantages of robotic precision.

Training Period

Robotic radiosurgery systems require dedicated training and workflow adaptation. Surgeons, physicists, and radiation therapists must become proficient with the system, and this takes time.

Training requirements may:

Slow the adoption process

Reduce the number of early procedures

Increase initial staffing costs

Limit utilization rates in the first year after installation

Manufacturers offer training programs, on site support, and workflow guidance to address this issue, but it remains a limiting factor in many regions.

Market Segmentation Summary

Robotic Radiosurgery Market – Further Segmented Into:

Revenue Type:

Capital Equipment, and Service and Maintenance Revenue

Competitive Analysis

Accuray

Accuray was the dominant competitor in the global robotic radiosurgery system market in 2024. Its CyberKnife platform has set the clinical benchmark for robotic radiosurgery due to its unique combination of imaging, real time motion tracking, and robotic beam delivery.

Accuray has continued to expand CyberKnife’s capabilities through strategic partnerships. In 2020, Accuray and Brainlab partnered to integrate Brainlab Elements planning software with CyberKnife, increasing its usefulness in neuro-radiosurgery. In 2022, Accuray partnered with Limbus AI to further enhance treatment planning using artificial intelligence. These ongoing improvements reinforce Accuray’s leadership in the market.

Zap Surgical

Zap Surgical is a smaller but growing competitor in the robotic radiosurgery market. The company offers the Zap-X Gyroscopic Radiosurgery platform, a self-shielded system designed for brain, head, and neck tumors.

The Zap-X system includes a robotic treatment table that allows for high precision beam alignment. Its lower price point, typically under $2 million, makes it more accessible for smaller centers seeking radiosurgery capabilities without the cost of a CyberKnife setup. Zap Surgical continues to gain attention in select markets due to its affordability and design simplicity.

Why This Report?

Health systems, surgeons, and investors need to understand the technologies shaping the future of precision cancer treatment. This report helps answer key questions such as:

Which companies are gaining or losing share in the robotic radiosurgery system market

How quickly is technology adoption expanding across regions

Which clinical, economic, and demographic factors are driving procedure volume

What role will partnerships, AI driven planning tools, and imaging integration play over the forecast period

Where the highest growth opportunities lie in capital equipment, disposables, and service revenue

This report is designed to support strategic planning, competitive analysis, pricing initiatives, and investment decisions.

About iData Research

iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.

Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.

Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.

Reports are available with flexible licensing to fit commercial, strategy, and investment workflows Show more